Contributions
Abstract: EP775
Type: E-Poster Presentation
Session title: Hodgkin lymphoma - Clinical
Background
Hodgkin disease, one of lymphoid malignancy that affects any age group with good results on standard chemotherapy. When relapse occurs, response rate decrease and survival becomes shorter. The introduction of anti-CD30 has improved results in relapsed patients; however, prognosis becomes very bad after further relapse.
Aims
to evaluate a new combination between dose-dense chemotherapy and lenalidomide in refractory Hodgkin lymphoma after at least 3 lines of chemotherapy and even after relapse on brentuximab
Methods
This is a prospective study conducted at Al Bairouni University Cancer Center in Damascus, Syria. We have included 75 patients with known HD in relapse after 3 lines of chemotherapy including Brentuximab. They received Cyclophosphamide 2gram/m2 + Mesna uroprotection in day 1, Procarbazin 100mg/m2 for 7 days, Gemcitabine 1000mg/m2 on days 1 and 8, prednisolone 1mg/kg from day 1 through day 14 with G-csf support for 5 days from day 9 through day 13. Treatment is repeated every 21 days for 6 cycles. Lenalidomide at a dose of 10 mg daily was given upfront for 6 months.
Results
Complete response was documented in 52 patients (69.3%) and partial response in 12 patients (16%) while disease progressed in the remaining 11 patients. At 3 years of follow up, another 12 patients progressed with a progression free survival rate of 69.3% and 61 patients were found alive after 3 years with an overall survival rate of 81.3%. hematologic toxicities dominated the scene especially long term neutropenia and thrombocytopenia which decreased adherence to protocol to 85%. 10 out 75 patients received brentuximab as a 3rd line. 8 out of the 10 patients received brentuximab showed a complete response (p.value 0.05).among the 11 progressed patients, 6 had a pulmonary infiltration (p value 0.03)
Conclusion
In the light of good response rate and acceptable toxicity profile, we can recommend this combination as a 4th line treatment in relapsed HD patient and as a salvage in those candidates for peripheral stem cell transplant; however, larger number of patients is mandatory in order to generalize these results.
Keyword(s): Chemotherapy, Hodgkin's disease, Survival
Abstract: EP775
Type: E-Poster Presentation
Session title: Hodgkin lymphoma - Clinical
Background
Hodgkin disease, one of lymphoid malignancy that affects any age group with good results on standard chemotherapy. When relapse occurs, response rate decrease and survival becomes shorter. The introduction of anti-CD30 has improved results in relapsed patients; however, prognosis becomes very bad after further relapse.
Aims
to evaluate a new combination between dose-dense chemotherapy and lenalidomide in refractory Hodgkin lymphoma after at least 3 lines of chemotherapy and even after relapse on brentuximab
Methods
This is a prospective study conducted at Al Bairouni University Cancer Center in Damascus, Syria. We have included 75 patients with known HD in relapse after 3 lines of chemotherapy including Brentuximab. They received Cyclophosphamide 2gram/m2 + Mesna uroprotection in day 1, Procarbazin 100mg/m2 for 7 days, Gemcitabine 1000mg/m2 on days 1 and 8, prednisolone 1mg/kg from day 1 through day 14 with G-csf support for 5 days from day 9 through day 13. Treatment is repeated every 21 days for 6 cycles. Lenalidomide at a dose of 10 mg daily was given upfront for 6 months.
Results
Complete response was documented in 52 patients (69.3%) and partial response in 12 patients (16%) while disease progressed in the remaining 11 patients. At 3 years of follow up, another 12 patients progressed with a progression free survival rate of 69.3% and 61 patients were found alive after 3 years with an overall survival rate of 81.3%. hematologic toxicities dominated the scene especially long term neutropenia and thrombocytopenia which decreased adherence to protocol to 85%. 10 out 75 patients received brentuximab as a 3rd line. 8 out of the 10 patients received brentuximab showed a complete response (p.value 0.05).among the 11 progressed patients, 6 had a pulmonary infiltration (p value 0.03)
Conclusion
In the light of good response rate and acceptable toxicity profile, we can recommend this combination as a 4th line treatment in relapsed HD patient and as a salvage in those candidates for peripheral stem cell transplant; however, larger number of patients is mandatory in order to generalize these results.
Keyword(s): Chemotherapy, Hodgkin's disease, Survival